Australia Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Australia Drug Delivery Devices Market Analysis

The Australia drug delivery devices market is valued at USD 4.59 billion in 2025 and is forecast to climb to USD 6.85 billion by 2030, registering an 8.31% CAGR over the period. Growth is underpinned by an aging population, a rising chronic-disease burden, and widespread use of the Pharmaceutical Benefits Scheme (PBS), which dispensed medicines to nearly 70% of residents during 2022. Government programs that shift care from hospitals to homes, such as Victoria’s Better at Home initiative, further expand demand for user-friendly devices.Intensifying R&D around microneedle patches, connected injectors, and orally delivered biologics is driving product innovation, while digital health investments are improving data flow and remote monitoring capability. Against this backdrop, manufacturers face higher Therapeutic Goods Administration (TGA) fees and strict combination-product rules that lift compliance costs.

Australia Drug Delivery Devices Market Trends and Insights

High Burden of Chronic Diseases and Ageing Population

Australia’s 1.3 million people living with diabetes in 2024 generated AUD 3.9 billion in direct health spending aihw.gov.au. Three-quarters of adults were dispensed at least one PBS medicine, and more than 85% of those with chronic conditions required ongoing pharmacotherapy.Age-related physiological changes alter drug absorption and clearance, heightening demand for delivery formats that optimise dosing precision and safety. Manufacturers that tailor devices to geriatric needs—larger buttons, audible cues, and connected adherence alerts—stand to gain as the senior cohort expands.

Government and Market Players Support for At-home Care & Remote Drug Delivery

Victoria’s Better at Home program channels AUD 698 million into virtual and in-home healthcare, serving more than 15,000 people a year. Queensland added AUD 27 million for similar services in its 2024-25 budget. Hospital-at-home models have lowered care costs by 30% while maintaining or improving outcomes, leading payers to reimburse home episodes at inpatient rates commonwealthfund.org. These policies create fertile ground for self-use injectors, wearable pumps, and connected inhalers that help patients manage therapy outside acute facilities.

Stringent TGA Combination-Product Compliance Costs

Application fees for new chemical entities included in a device run to AUD 18,872, with evaluation charges of AUD 76,055 and annual levies topping AUD 1,500 for Class III devices. These rising costs weigh heavily on start-ups and academic spin-outs, delaying market entry and, in some cases, redirecting R&D overseas.

Other drivers and restraints analyzed in the detailed report include:

1. Rising Penetration of Biosimilars and Targeted Therapies Requiring Novel Delivery Formats
2. Digital Health Integration with Connected Injectors & Pumps
3. Needlestick Injury Litigation and Risks Associated with Various Devices

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Injectable systems held 31.63% of the Australia drug delivery devices market share in 2024, a position cemented by growing biologics use and rising chronic-disease prevalence. Connected pen injectors that transmit dosage logs to clinician dashboards are gaining traction among endocrinologists and rheumatologists. The Australia drug delivery devices market size attached to transdermal patches is projected to grow at 12.29% CAGR between 2025 and 2030, spurred by microneedle breakthroughs that improve payload capacity without compromising comfort. Collaboration between the Transdermal and Transmucosal Drug Delivery Research Group and Bionyeri Pty Ltd created a microneedle patch for acute pain episodes, illustrating domestic innovation.

Infusion-pump makers are integrating Bluetooth and closed-loop algorithms in anticipation of a national subsidy for insulin pumps proposed to begin mid-2025. Implantables, ocular inserts, and nasal devices round out the portfolio, each targeting niche clinical requirements. A recent health-technology assessment found intrathecal pumps improve quality of life for refractory cancer pain, though upfront costs remain high.

Injectables delivered 44.57% of 2024 revenue within the Australia drug delivery devices market. High therapy adherence rates and predictable pharmacokinetics keep parenteral administration the default for many biologics. Inhalation devices account for a sizeable fraction, supported by ongoing upgrades to dry-powder carriers for obstructive-airway disease. The oral-mucosal channel is forecast to post a 10.23% CAGR as developers exploit sublingual routes to bypass first-pass metabolism.

Transdermal technologies continue to benefit from work on novel permeation enhancers and herbal patches that reduce gastrointestinal side effects. Nasal formulations appeal to neurologists for rapid central-nervous-system access; nanoparticle-gel hybrids recently showed 86%–96% encapsulation efficiency, signalling commercial promise.

The Australia Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps and More), Route of Administration (Injectable, Inhalational, Transdermal and More), Application (Cancer, Cardiovascular, Diabetes and More), End User (Hospitals, Ambulatory Surgical Centers, and More). The Market and Forecasts are Provided in Terms of Value (USD).

List of Companies Covered in this Report:

1. Beckton Dickinson
2. GlaxoSmithKline
3. Novartis
4. Terumo
5. Novo Nordisk
6. Johnson & Johnson (Johnson MedTech & Janssen)
7. Sanofi
8. Pfizer
9. AstraZeneca
10. Viatris
11. Teva Pharmaceutical Industries
12. Bayer
13. Medtronic
14. Insulet
15. Tandem Diabetes Care
16. Roche
17. West Pharmaceutical Services
18. Gerresheimer
19. Ypsomed
20. B. Braun Australia Pty Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support